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httpcense.Abstract Background: Obstructive sleep apnea (OSA) has been associated with cardiovascular
complications. The overnight repetitive hypoxia represents a form of oxidative stress in the vascu-
lature which may activate the oxidant-sensitive, proinﬂammatory transcription factor nuclear factor
jB (NF-jB), affecting endothelial function and atherosclerosis.
Aim: We investigated whether the endothelial alterations attributed to OSA rather than to other
confounding factors. Also, the production of inﬂammatory cytokine nuclear factor-kappa b (NF-
Kb) was investigated as the molecular mechanism involved in vascular endothelial dysfunction with
OSA.
Material and methods: Sixty subjects underwent attended nocturnal polysomnography were
grouped by apnea hypopnea index: control (AHI<5/h) and OSA cases (AHI>5/h) the cases were
further classiﬁed according to age and BMI into subgroup IIA: OSA, non-obese, middle age
(35–52 y), subgroup IIB: OSA, non-obese, older age group (55–68 y), subgroup IIIA: OSA, obese,
middle age group (35–52 y) and subgroup IIIB: OSA, obese, older age group (55–68 y).pnea; AHI, Apnea hypopnea
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470 E. El-Shamy et al.A morning venous blood sample was obtained. Neutrophils were isolated, and NF-jB activity
was determined. Plasma sVCAM-1 was assayed by enzyme-linked immunosorbent assay and
ﬂow-mediated dilation (FMD) was performed.
Results: NF-jB activation and plasma level of sVCAM-1 were signiﬁcantly increased in OSA
patients as compared to the control group and there was no signiﬁcant difference between the obese
and non-obese cases also no signiﬁcant difference between the middle and old age cases. The degree
of NF-jB activation was positively correlated with indices of apnea severity(r= 0.938; p< 0.001).
FMD was signiﬁcantly decreased in OSA patients as compared to the control group.
Conclusion: These ﬁndings suggested that OSA is an independent risk factor for cardiovascular
morbidity also that OSA leads to NF-jB activation, which may constitute an important pathway
linking OSA with systemic inﬂammation and cardiovascular disease.
ª 2012 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.Introduction
The endothelium is a thin mono cellular layer that covers all the
inner surface of the blood vessels, separating the circulating
blood from the tissues. In the past, the endothelium was consid-
ered to be inert and inactive, However, this view has been com-
pletely changed with founding that endothelial cells are dynamic
and exert signiﬁcant autocrine, paracrine and endocrine actions
that inﬂuence smooth muscle cells, platelets and peripheral leu-
cocytes. It releases agents that regulate vasomotor function, trig-
ger inﬂammatory processes, and affect hemostasis [1].
It was postulated that impaired endothelial function exerts
an important role in the development of cardiovascular dis-
eases associated with obstructive sleep apnea [2].
Obstructive sleep apnea (OSA) is characterized by repeated
episodes of apnea during sleep. Each cycle of apnea and resump-
tion of ventilation is accompanied by arterial oxyhaemoglobin
desaturation and resaturation. This overnight repetitive hypoxia
and reoxygenation may represent a form of oxidative stress,
which generates reactive oxygen species [3]. Many investiga-
tions, had established that OSA is an independent risk factor
for many cardiovascular diseases. OSA is often associated with
risk factors as aging, obesity, arterial hypertension, diabetes
mellitus and ischemic heart disease. This increase in cardiovas-
cular morbidity in patients with OSA is attributed to accelerated
atherosclerosis. An early event of pathophysiologic importance
in the atherosclerotic process is endothelial dysfunction [4].
Endothelial dysfunction is a broad term that was initially
identiﬁed as impaired vasodilation due to diminished produc-
tion or availability of nitric oxide (NO) and/or an imbalance
in the relative contribution of endothelium-derived relaxing
and contracting factors, such as endothelin-1 (ET-1), angioten-
sin, and oxidants. A broader understanding of the term would
include not only reduced vasodilation but also a proinﬂamma-
tory and prothrombic state associated with dysfunction of the
endothelium [5]. Endothelial cells regulate leucocyte movement
into tissues via carefully regulated processes involving adhe-
sion molecules. Adhesion molecules mediate the adhesion of
leucocytes to the endothelium by binding to speciﬁc ligands
on the leucocytes. Adhesion molecules allow movement of
activated inﬂammatory cells out of the circulation to the site
of infection or injury whilst at the same time, maintaining
the integrity of the endothelium itself [6].
Endothelial cells express E-selectin, P-selectin, ICAM-1 and
VCAM-1. VCAM-1 binds monocytes and T lymphocytes, theﬁrst step of invasion of the vessel wall by inﬂammatory cells.
Once adherent, the monocytes transmigrate into the tunica in-
tima, the innermost layer of the arterial wall [7]. Once within
the arterial intima, the monocytes develop into macrophages
and begin to express scavenger receptors, that internalize mod-
iﬁed lipoproteins. Internalization of these lipoprotein particles
gives rise to lipid-laden macrophages or foam cells, which
characterize early atherosclerotic lesions [8].
Oxidative stress may activate endothelial cells and leuko-
cytes, resulting in increased expression of several glycopro-
teins, including the adhesion molecules as vascular cell
adhesion molecule-1 (VCAM-1) [9]. These molecules facilitate
the attachment of macrophages and leukocytes and their
migration to the subendothelial space, where their products
facilitate the atherogenic process. Adhesion molecules on these
cells are a well-deﬁned early marker of premature atherosclero-
sis [8].
This reactive oxygen species may also activate the oxidant-
sensitive, proinﬂammatory transcription factor nuclear factor
kappa b (NF-Kb), increasing systemic inﬂammation [10].
NF-jB is one of the most important redox responsive tran-
scription factors, which has a role in the activation of the pro-
moter activity of over 200 genes of many cytokines, growth
factors, adhesion molecules and enzymes involved in immune
and inﬂammatory responses, many of which play an important
role in the pathophysiology of athrescleosis and other cardio-
vascular diseases [11]. Thus, it is possible that OSA could pro-
mote systemic inﬂammation and cardiovascular pathology by
inducing NF-jB-mediated expression of proinﬂammatory
and proatherogenic genes.
Several tools has been done to assess the endothelium dys-
function as measurement of circulating markers of endothelial
cell damage as ICAM-1, VCAM-1, E-selectin and plasma
endothelin-1. A widely reported noninvasive method to assess
endothelial dysfunction, relies on high-resolution ultrasound
measurements of ﬂow-mediated dilation of the brachial artery
to reactive hyperemia after a short period of forearm ischemia
[12].
Aim of the work
This work was designed to investigate whether OSA is associ-
ated with endothelium dysfunction compared with age and
body mass index (BMI)–matched control subjects as indicated
by VCAM-1 and FMD. Also, to investigate the production of
Study of endothelial dysfunction and vascular inﬂammation in sleep apnea, obesity and aged humans 471inﬂammatory cytokine nuclear factor-kappa b (NF-Kb) as the
molecular mechanism involved in vascular endothelial dys-
function with OSA.
Subjects and methods
The present study was carried out on 60 persons referred to
sleep laboratory in the chest department in the main University
hospital. The inclusion criteria for the studied subjects were;
patients with newly diagnosed obstructive sleep apnea (OSA)
[deﬁned as an apnea-hypopnea index (AHI) of 5 obstructive
events per hour of sleep], no any other clinical diseases as
assessed by medical history, physical examination, blood
chemistry, and resting ECGs. However, the exclusion criteria
were smoking, diabetes mellitus, and subjects taking any
medications or herbal supplements. The studied subjects were
subdivided according to their age, body mass index and poly-
somnography data into 3 groups:
Group I: (control group) consisted of 20 nonsmokers
healthy volunteers (BMI < 25) (AHI < 5); Group II (OSA,
non-obese group) consisted of 20 non-obese OSA patients
(BMI < 25) (AHIP 5) and Group III (OSA, obese group)
consisted of 20 obese OSA patients (BMI > 25) (AHIP 5).
All the 3 groups were subdivided into two subgroups 10 per-
sons each, subgroup A (Middle age group 35–52 y) and sub-
group B (old age group 55–68 y).
All the participants were subjected to; history taking, clini-
cal examination, routine laboratory investigations, resting
ECG, assessment of anthropometric data using fat absorbeti-
ometer in the physiology department. Nocturnal polysomnog-
raphy at sleep lab chest department, Alexandria university
hospital were done and ﬂow-mediated dilation of the brachial
artery (FMD) was done using high-resolution ultrasonography
in the Radiology department [13].
Moreover, fasting blood samples were collected from all
participants between 9 and 11 AM within 48 h of polysomnog-
raphy for estimation of:
NF-jB by ELISA
Neutrophils (95–98% purity) were isolated using Ficoll–Paque
centrifugation and were subsequently puriﬁed by dextran sed-
imentation and hypotonic lysis of residual erythrocytes. Puriﬁ-
cation of cellular nuclear extracts using Cayman’s nuclear
extraction kit to isolate nuclear protein. NF-jB was quantiﬁed
using NF-jB (human P50/P65) combo transcription factor as-
say kit (Caymann) [14].
o Soluble vascular cell adhesion molecule-1 (sVCAM-1) using
ELIZA Kit [15].Statistics
The values of the measured parameters were expressed as
mean ± SD or as median (min–max). The difference between
the studied groups was determined using ANOVA test (F-test)
and The Kruskal-Wallis test (H-test). Pearson’s correlation
coefﬁcient was performed for evaluating the biochemical and
radiological variables. P< 0.05 values were considered signif-
icant. All statistical analyses were processed using SPSS for
windows Version 18.Results
Clinical characteristics and laboratory values of the patients
upon initial admission are summarized in Table 1. All the 3
groups were subdivided into two subgroups, subgroup A
(Middle age group 35–52 y) and subgroup B (old age group
55–68 y).It was observed that BMI is signiﬁcantly increased
in group III as compared to the other two groups. There were
no signiﬁcant differences between the 3 groups in the fasting
blood sugar and serum cholesterol levels.Sleep studies data
AHI, ODI, Mini PaO2, and average pulse rate are shown in
Table 2. Apnea-hypopnea index (AHI) and oxygen desatura-
tion index (ODI) increased signiﬁcantly as expected between
the control group I with AHI (2.25 ± 1.16) and ODI
(1.53 ± 0.32) as compared to OSA patient with AHI
(24.07 ± 15.14) and ODI (23.49 ± 22.07).
Mini PaO2 was signiﬁcantly decreased in OSA patients
(76.20 ± 6.76) as compared to the control group I
(92.45 ± 1.66) and average pulse rate was signiﬁcantly in-
creased in OSA patients as compared to the control group.
Endothelial dysfunction and vascular inﬂammation investi-
gations are shown in Table 3. It is observed that NF-jB
activation was signiﬁcantly increased in OSA patients as com-
pared to the control group. On the other hand there was no
signiﬁcant difference between the obese and non-obese cases
also no signiﬁcant difference between the middle and old
age cases.
Serum sVCAM-1 was signiﬁcantly increased in OSA pa-
tients as compared to the control group. On the other hand
there was no signiﬁcant difference between the obese and
non-obese cases also no signiﬁcant difference between the mid-
dle and old age cases. However, there was a signiﬁcant differ-
ence in the control group between the middle age as compared
to the old age subgroup.
The reactive dilatation of the brachial artery was signiﬁ-
cantly decreased in OSA patients as compared to the control
group. On the other hand there was no signiﬁcant difference
between the obese and non-obese cases also no signiﬁcant dif-
ference between the middle and old age cases. However, there
was a signiﬁcant difference in the control group between the
middle age as compared to the old age subgroup.Correlation study between NF-jB activity, sVCAM-1 and the
severity of OSA
n Neutrophil NF-jB activity correlates with indices of OSA
severity as assessed by AHI. Neutrophil NF-jB activity
was positively correlated with AHI (r= 0.938;
p< 0.001), ODI (r= 0.927; p< 0.001), and negative with
Mini PaO2 (r= 0.888; p< 0.001).
n A signiﬁcant strong positive correlation was found between
sVCAM-1 level and AHI (r= 0.914, p< 0.001) and also
with the degree of hypoxaemia as assessed by ODI
(r= .928, p< 0.001) and strong negatively correlation
with Mini PaO2 (r= .877, p< 0.001) (see Table 4).
T
a
b
le
1
C
li
n
ic
a
l
ch
a
ra
ct
er
is
ti
cs
o
f
th
e
3
st
u
d
y
g
ro
u
p
s.
I
II
II
I
T
es
t
st
a
ti
st
ic
(p
-v
a
lu
e)
A
B
A
B
A
B
A
g
e
(y
ea
rs
)
3
9
±
2
.9
4
5
9
.8
±
1
.7
5
*
3
8
.7
±
2
.8
3
5
9
.3
±
1
.6
9
*
4
0
±
3
.6
8
5
8
.2
±
2
.0
4
*
F
=
1
7
2
.8
1
(<
.0
0
1
)
B
M
I
(k
g
/m
2
)
2
3
.5
5
±
0
.6
3
2
3
.9
2
±
0
.6
0
2
3
.9
9
±
0
.6
0
2
4
.3
6
±
0
.7
4
4
6
.7
7
±
1
6
.1
3
*
3
9
.2
9
±
4
.3
0
*
F
=
2
1
.9
8
(<
.0
0
1
)
S
ex
M
/F
7
/3
6
/4
7
/3
6
/4
7
/3
7
/3
F
a
st
in
g
b
lo
o
d
g
lu
co
se
(m
g
/d
l)
8
7
.2
0
±
1
2
.6
9
8
7
.4
0
±
7
.7
2
8
4
.0
0
±
1
2
.8
4
9
0
.4
0
±
7
.5
9
8
3
.2
0
±
1
1
.3
7
8
9
.1
0
±
9
.7
9
F
=
7
1
5
(.
6
1
5
)
S
er
u
m
C
h
o
le
st
er
o
l
(m
g
/d
l)
1
7
2
.5
0
(1
5
2
1
9
7
)
1
8
8
.0
0
(1
5
7
1
9
7
)
1
8
1
.5
0
(1
5
7
1
9
3
)
1
7
5
.0
0
(1
4
5
1
9
7
)
1
8
9
.0
0
(1
7
5
1
9
8
)
1
8
9
.5
0
(1
7
9
1
9
8
)
H
=
1
1
.5
4
(.
0
4
2
)
V
a
lu
es
a
re
m
ea
n
±
S
D
.
E
x
ce
p
t
se
ru
m
ch
o
le
st
er
o
l
is
m
ed
ia
n
(m
in
–
m
a
x
).
*
p
<
0
.0
5
v
s
g
ro
u
p
IA
.
472 E. El-Shamy et al.Discussion
The vascular endothelium participates in control of various
vascular functions through regulation of vasoactive media-
tors in response to physical or biochemical stimuli in the body
[1]. Endothelial injury, at cellular level or tissue level, is an
important initial event in atherogenesis, preceding thickening
of intima and formation of atherosclerotic plaques [8]. Endo-
thelial dysfunction was shown to have a predictive value for
cardiovascular events in patients with chest pain and/or cor-
onary artery disease [16]. It was shown also to be the early
event in accelerated atherosclerosis attributed to OSA [4].
Obstructive sleep apnea (OSA) is currently considered to
be an inﬂammatory disorder. Evidence suggests that the
chronic intermittent hypoxia and, possibly, sleep loss and
fragmentation associated with OSA increase the levels of var-
ious markers of inﬂammation. In particular, increased levels
of inﬂammatory cytokines, adhesion molecules, and activa-
tion of circulating neutrophils [8].
The present work was designed to assess the development
of endothelial dysfunction and inﬂammation in patients with
OSA compared with age and body mass index (BMI)–
matched control subjects.
Regarding the NF-jB activity in circulating neutrophils of
OSA patients and the controls the current data demonstrated
signiﬁcant increase NF-jB activity in circulating neutrophils
of OSA patients. Moreover, the degree of NF-jB activity is
positively correlated with OSA severity. Neutrophil NF-jB
activity was positively correlated with AHI, ODI, and mini
Pao2. It has been well documented that NF-jB activation is
an integral part of the pathophysiology of numerous cardio-
vascular disorders [11]. our ﬁndings suggest that NF-jB could
be an important molecule linking the patho-physiological
consequences of OSA with cardiovascular disease.
There is ample evidence supporting the essential role of
NF-jB activation in the pathogenesis of various cardiovascu-
lar diseases. Many genes, whose expression is regulated by
NF-jB, have been implicated in atherogenesis and cerebro-
vascular disease [11,17]. The relevance of NF-jB activation
in OSA is demonstrated by the presence of elevated levels
of the products of several NF-jB controlled genes in OSA pa-
tients. Data from previous studies have shown that OSA pa-
tients have increased levels of the adhesion molecules sE-
selectin, sVCAM-1, ICAM-1, and L-selectin as well as the
cytokines interleukin (IL)-6 and tumor necrosis factor
(TNF)-a, all of which are produced by NF-jB regulated
genes [18]. Because these inﬂammatory proteins have been
shown to play a crucial role in the pathogenesis of atheroscle-
rosis [17], these observations collectively suggested that OSA
may contribute to atherogenesis by stimulating NF-jB, with
subsequent activation of cell adhesion and other proinﬂam-
matory pathways.
It has been postulated that intermittent hypoxia associated
with recurrent obstructive apneas is a crucial pathophysiolog-
ical feature of OSA which generates increased ROS [19].
These free radicals may then activate oxidant-sensitive tran-
scription factors such as NF-jB. As a result, production of
proinﬂammatory mediators and adhesion molecules is in-
creased, in addition to activation of neutrophils and endothe-
lial cells. Increased adhesion of activated inﬂammatory cells
Table 3 The NF-kB activity, serum s-VCAM-1 and FMD in the studied groups.
Group
I II III
A B A B A B
NF-KB(lg/well) 5.50a 5.00a 21.00a 21.00a 19.50a 25.00a
(3.0–8.0) (2.00–8.0) (15.0–65.0) (15.0–65.0) (15.0–58.0) (14.0–65.0)
sVCAM (ng/ml) 538.00a 762.00c 1617.0b 1686.00b 1375.00b 1960.00b
(470–708) (724–816) (1224–2304) (1492–3002) (1260–2574) (1242–4378)
FMD% 9.10a 7.90c 4.30b 4.20b 4.85b 3.65b
(8.10–9.60) (7.10–8.20) (3.10–5.60) (2.90–4.60) (3.20–5.40) (2.50–4.50)
a,b,c Values are median (min–max). The groups with the same small letter have no signiﬁcant difference.
Table 2 sleep studies data AHI, ODI, Mini PaO2, and average pulse rate.
Control Cases t-test
Mean SD Mean SD t p-value
AHI (events/h) 2.25 1.16 24.07* 15.14 9.06 <.001
ODI (events/h) 1.53 .32 23.49* 22.07 6.29 <.001
Mini PaO2 (mmHg) 92.45 1.66 76.20* 6.76 14.35 <.001
Average pulse (beats/min) 66.90 3.67 84.13* 10.39 9.38 <.001
Values are mean ± SD.
* p< 0.05 vs control group I.
Table 4 Correlation between NF-jB activity, sVCAM-1 and
severity of OSA.
AHI ODI Mini PaO2
NFKB r(p-value) .938** .927** .888**
(<.001) (<.001) (<.001)
sVCAM- R .955** .928** .877**
1 (p-value) (<.001) (<.001) (<.001)
Study of endothelial dysfunction and vascular inﬂammation in sleep apnea, obesity and aged humans 473to the endothelium is an important factor contributing to
endothelial dysfunction and atherogenesis [8,9].
In Animal studies, Shuo et al, 2011 had studied the systemic
production of inﬂammatory factors and activation of NF-jB
in response to different levels of intermittent hypoxia in 160
male Wistar rats, which has a typical breathing pattern of
OSA. They have found that the correlation of NFjB activa-
tion under intermittent hypoxia implies an important role of
this transcription factor in inﬂammation-induced cardiovascu-
lar damage occurring during OSA [20]. Furthermore, other
in vitro studies done by Ryan and colleagues, 2005 reported
that, in an in vitro cell culture model, alternating cycles of hy-
poxia and re-oxygenation resulted in selective and dose-depen-
dent activation of inﬂammatory NF-jB-dependent pathways
[21].
These data go in line with other studies by Aung et al, 2006
who reported that neutrophils demonstrated signiﬁcantly
greater NF-jB activity in the mild to moderate and severe
OSA groups than in the control subjects and this increased
neutrophil NF-jB activity is reversed by CPAP treatment
[10], Yamauchi et al, 2006 have measured activation of the
NF-jB, in nine age-matched, nonsmoking, and non-hyperten-
sive men with OSA symptoms and seven similar healthy sub-
jects were measured at the same time and after the nextnight of continuous positive airway pressure (CPAP). NF-kB
activity in the OSA group were signiﬁcantly higher than in
the control group. One night of CPAP resulted in a reduction
in NF-kappaB. They concluded that NF-kappaB activation
occurs with sleep-disordered breathing. Such activation of
NF-kappaB may contribute to the pathogenesis of atheroscle-
rosis in OSA patients [22].
The present study has focused on activation of NF-jB in
circulating neutrophils. While both monocytes and neutrophils
have been implicated in the inﬂammatory processes leading to
atherosclerosis, we chose to investigate circulating neutrophils
since Richard Schulz et al, 2000 had demonstrated the release
of superoxide from circulating neutrophils of patients with
OSA in response to ex vivo stimulation, and is reversible with
nasal CPAP therapy [23]. Furthermore, the neutrophil is
known to play an important role in cardiovascular disease
since inﬁltration of neutrophils into atherosclerotic plaque
has been associated with plaque rupture and the occurrence
of acute coronary events [24]. However, it is likely that OSA
may also activate NF-jB in other cell types such as endothelial
cells.
This study also demonstrated that there was no signiﬁcant
difference between the obese and non-obese cases also no sig-
niﬁcant difference between the middle and old age cases which
means that the co-morbid factors are not inﬂuencing our ﬁnd-
ings. This evidence indicates that the observed increase in NF-
jB activity is causally related to OSA, rather than to comorbid
factors or to differences in BMI between groups. Thus, while
obesity has been characterized as a proinﬂammatory state
[25], and we cannot completely rule out a contribution of obes-
ity itself to NF-jB activity, our ﬁndings support an indepen-
dent effect of OSA on NF-jB activation as our study use a
lean OSA group to deﬁnitely separate effects of obesity from
those of OSA.
474 E. El-Shamy et al.To conﬁrm the biologic relevance of the observed change in
NF-jB, we measured serum levels sVCAM-1, an important
NF-jB controlled gene product, in OSA patients and in con-
trol subjects. There was a signiﬁcant increase in the biochemi-
cal marker (sVCAM-1) in OSA patients as compared to age
matched control groups.
Furthermore our ﬁndings have shown that the concentra-
tion of circulating adhesion molecules correlated with the
severity of sleep apnea. The current study also showed a signif-
icant relation between cellular adhesion molecules and the
severity of hypoxemia as indicated by the ODI and mini
PaO2 suggesting that the risk of cardiovascular events is per-
haps related to the intermittent hypoxia observed during sleep
and the level of hypoxaemia. It is plausible that intermittent
hypoxia promotes oxygen radical formation [26] that leads to
activation of transcriptional factors that upregulate the genetic
expression of adhesion molecules [27].
Although the pathologic role of these cellular adhesion
molecules in OSA is uncertain, studies have shown elevated
circulating levels of adhesion molecules in subjects with OSA
compared to those without sleep-disordered breathing [18].
Various circulating markers of endothelial dysfunction, includ-
ing nitric oxide, soluble cell adhesion molecules, ﬁbrinogen,
and plasminogen activator inhibitor, have been reported to
be altered in OSA [19,28]. This coincides with recent studies
of Bernabe Jurado-Gamez et al,2012 who found that patients
with OSA and greater intermittent hypoxia had worse endo-
thelial function, and higher levels of ICAM-1 and P-selectin
[29]. Hypoxia has been implicated in the induction of interleu-
kin-1 and cellular adhesion molecules gene expression [30].
The present data conﬁrm previous results that OSA syn-
drome is associated with a rise in circulating levels of adhesion
molecules. Aung. et al, 2006 have found that the circulating
levels of VCAM-1 are signiﬁcantly increased in patients with
OSA compared with those of a matched control group.[10]
Ohga and coworkers, 1999 reported increased levels of
ICAM-1, VCAM-1, and L-selectin levels in seven patients with
OSA compared to a control group of ‘‘normal subjects’’. The
authors suggested that the repetitive hypoxic stress during
sleep might induce activation and provoke sustained release
of these inﬂammatory mediators. Since cellular adhesion mol-
ecules mediate cellular interactions and transmigration of leu-
kocytes across the vascular endothelial wall [31]. our ﬁndings
suggest that OSA could contribute potentially to the inﬂam-
matory process implicated in atherogenesis.
On the other hand, other studies have found no signiﬁcant
change. As Klein et al, 1995 who studied the in vitro inﬂuences
of hypoxia on endothelial cell proliferation and expression of
cell adhesion molecules. They found that the presentation of
ICAM-1, VCAM-1, and E-Selectin was not affected by hypox-
ia or even reduced and they are not appear to be the major as-
pect in hypoxic injury [32].
The reactive dilatation of the brachial artery was assessed
as a physical marker of endothelial dysfunction. FMD was sig-
niﬁcantly decreased in OSA patients as compared to the con-
trol group. On the other hand there was no signiﬁcant
difference between the obese and non-obese cases also no sig-
niﬁcant difference between the middle and old age cases. This
indicates impaired reactive hyperaemia in OSA cases which
indicates endothelial dysfunction.
The mechanisms of vascular response to vessel occlusion
followed by reactive hyperemia are clearly complex, involvingmyogenic, neurogenic, and vasculogenic components, medi-
ated by a variety of metabolic alterations and vasoactive fac-
tors. The exact mechanisms apparently differ with vascular
beds and evoking stimuli [33]. Flow-mediated dilation refers
to nitric oxide-mediated vasodilatation resulting from shear-
mediated activation of endothelial nitric oxide synthase in re-
sponse to an acute increase in blood ﬂow [13]. The test has
been shown to be accurate and reproducible [34].
Previous studies on vascular endothelial function in OSA
have shown conﬂicting data. These studies have used different
methods for evaluation of vascular endothelial function. For
instance, Blunted vasodilation in response to infusion of ace-
tylcholine, a vasodilator that stimulates endothelial release of
nitric oxide, was demonstrated in forearm resistance vessels
using occlusion plethysmography [35], but not conﬁrmed in
another study [36]. Impaired relaxation response to bradykinin
in the forearm venous vasculature has been reported, suggest-
ing endothelial dysfunction in the venous vasculature [37].
Using ultrasound Doppler method similar to ours, Mathias
Grebe et al, 2006 had measured ﬂow-mediated dilation (FMD)
of the brachial artery by ultrasound in 10 otherwise healthy,
untreated patients with OSA and 10 age-and sex-matched con-
trol subjects without sleep-disordered breathing before and
after intravenous injection of the antioxidant vitamin C. They
found that the reduced endothelial-dependent vasodilation in
untreated patients with OSA acutely improves by the free rad-
ical scavenger vitamin C. These results are in favor of oxidative
stress being responsible for the endothelial dysfunction in OSA
[38].
In contrast to our ﬁndings, another study found no signif-
icant difference in conduit–vessel dilation between sleep apnea
and control subjects. In that study, subjects underwent con-
duit–vessel studies at least 1 hour after resistance–vessel stud-
ies, which involved intra-arterial infusion of acetylcholine,
nitroprusside and verapamil, and residual effect of drugs on
the vasculature, which affected their response to reactive
hyperemia, cannot be completely excluded [39].
To exclude the effect of obesity, we compare the FMD in
lean and obese OSA patients, and there was no signiﬁcant dif-
ference between both groups. In another study, OSA and sub-
jects without OSA were matched for obesity, and the body
mass index was not a signiﬁcant independent determinant of
FMD on multiple regression analysis. The change in FMD
with treatment of OSA without any concomitant change in
body weight and the use of a control group who did not receive
nCPAP treatment provided further evidence that the improve-
ment in endothelial function in this study sample, most of
whom were obese, was attributed to the use of nCPAP,
whereas a placebo effect could not be deﬁnitively excluded.
OSA, therefore, may be associated with functional impairment
(‘‘a premature aging effect’’) on the endothelium and on arte-
rial stiffness [40].Conclusions
The ﬁndings of endothelial dysfunction in otherwise healthy
subjects with OSA lend strong circumstantial evidence to an
independent contribution of OSA to atherosclerosis. The pres-
ent data also provide evidence for activation of the proinﬂam-
matory transcription factor NF-jB in OSA. This ﬁnding lends
further support to an emerging hypothesis which postulates
Study of endothelial dysfunction and vascular inﬂammation in sleep apnea, obesity and aged humans 475that OSA contributes to cardiovascular disease by increasing
systemic inﬂammation.References
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